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Abstract. TRPM8 ion channels, the primary cold sensors in humans, are activated by 
innocuous cooling (< 28 ºC) and cooling compounds (menthol, icilin), and are 
implicated in sensing unpleasant cold stimuli, as well as in mammalian 
thermoregulation. Over-expression of these thermoregulators in prostate cancer and in 
other life-threatening tumors, along with their contribution to an increasing number of 
pathological conditions, opens a plethora of medicinal chemistry opportunities to 
develop receptor modulators. This Perspective seeks to compile current known 
modulators for this ion channel, since both agonists and antagonists may be useful for 
the treatment of most TRPM8-mediated pathologies. We primarily focus on SAR data 
for the different families of compounds and the pharmacological properties of the most 
promising ligands. Furthermore, we also address the knowledge about the channel 
structure, although still in its infancy, and the role of the TRPM8 protein signalplex to 
channel function and dysfunction. We finally outline the potential future prospects of 
the challenging TRPM8 drug discovery field. 
 1. INTRODUCTION 
The family of TRP channels comprises 28 members, clustered in 8 subfamilies (TRPA, 
TRPC, TRPM, TRPML, TRPN, TRPP, TRPV, and TRPY) that function as molecular 
cellular signal integrators.
1-4
 Among them, the so-called thermoTRPs are activated by 
different temperatures, ranging from painful levels of heat (TRPV1 and TRPV2), to 
non-painful warmth (TRPV3 and TRPV4), innocuous cool (TRPM8) and noxious cold 
(TRPA1). Despite their role as sensors for temperature, these channels also act in 
response to voltage, mechanical stimuli, and endogenous and exogenous molecules.
5-9
 It 
has been shown that different syndromes result from mutations or changes in the 
activities of TRP channels, including sensory deficits, abnormal sensitivity to pain, 
certain cancers, asthma, and even cardiovascular, gastrointestinal and neurodegenerative 
diseases. This fact makes TRP channels exciting targets for drug development, although 
the efforts made in this field, especially in the search for TRPV1 antagonists, have not 
yet been fully successful, and the first compound in clinical use is still to come.
9, 10
  
Along with TRPV1 and TRPA1, Transient Receptor Potential Melastatin 8 (TRPM8, 
also known as Trp-p8 or MCR1) is one of the most studied thermoTRP channels in 
relation to its physiological and pathological implications, and the search for new 
modulators occupies the efforts of different pharmaceutical companies and academic 
groups. Initially identified from the prostate,
11
 TRPM8 channels are widely distributed 
in different tissues (subsets of sensory neurons innervating skin and mucosae,
12-14
 the 
male urogenital tract
15
, lung epithelium cells
16
, and artery myocytes
17
), although their 
specific role in many cases still remains to be completely elucidated. This is a Ca
2+
-
permeable, nonselective cation channel that exhibits polymodal gating mechanisms, 
being activated by innocuous cool to cold temperatures (10-28 °C),
18, 19
 membrane 
depolarization,
20, 21
 cooling agents like menthol and icilin,
20, 22
 and different synthetic 
molecules.
12, 23-25
 The enhanced sensitivity to innocuous cold (allodynia) and to mildly 
noxious stimuli (hyperalgesia), occurring after nerve injury or inflammation, have been 
correlated with an augmented expression of TRPM8 in sensory neurons.
26, 27
 Other 
experimental evidences indicate that activation of TRPM8 channels resulted in 
attenuating pain in inflammatory and acute pain states,
28
 as commented in more detail in 
the following section. In recent years, as discussed in section 3, the up-regulation of 
TRPM8 expression has also been correlated with the evolution of androgen-sensitive 
prostate cells and other malignancies.
11, 29
 
As for other ion channels, a point of debate arises from the possibility that both agonists 
and antagonists can serve for the same therapeutic indication. This comes from the fact 
that these channels do not have two discrete states only, open (conducting) and closed 
(non-conducting), but also an inactivated/desensitized state, which after long exposure 
to agonists or continuous stimulation are not able to conduct ions across, because the 
channel gate closes (Figure 1).
30
 For TRP channels, calcium entry into the cell seems to 
be the primary event leading to desensitization.
30
 It has been demonstrated that TRPM8 
channels are activated by PI(4,5)P2, through putative interactions with the TRP domain, 
and that cold or menthol increases the apparent affinity of TRPM8 channels for this 
endogenous ligand.
31
 More importantly, desensitization of TRPM8 receptor, and 
probably of other TRP channels, is mediated by PI(4,5)P2 depletion, triggered by a 
Ca
2+
-sensitive phospholipase C (most likely PLC1) stimulated after cell Ca2+ influx, 
and that resulted in the PI(4,5)P2 hydrolysis.
31, 32
   
 Figure 1. Simplified scheme of TRPM8 channels at different states (resting, open, 
desensitized, and blocked). 
 
The implications of TRPM8 channels in the above indicated physiopathological 
conditions underscore their potential as valuable pharmacological targets for therapeutic 
intervention, not only for the diagnosis/prognosis of prostate cancer and other tumors, 
but also in the search for innovative analgesics and antitumor agents.
10, 33
 Although 
some comprehensive reviews on the pharmacology and therapeutic potential of TRPM8 
modulators have already appeared,
12, 23-25, 33
 here we offer a general overview of the 
field, with focus on medicinal chemistry aspects extracted from primary research 
articles and patents. Sections 5 and 6 are devoted to describe the most important agonist 
and antagonist chemotypes, with indication of structure-activity relationships, whenever 
possible, and the in vitro and in vivo pharmacological characterization of the most 
prominent derivatives. The progression of a few compounds into clinical development 
will be also commented upon. Some recent contributions related to the indirect 
assessment of the TRPM8 structure (section 7), and the advanced knowledge of the 
modulation of these channels by different endogenous molecules (section 8), are also 
included. This information could provide important clues for upcoming drug discovery 
programs based in this challenging but high potential therapeutic target.  
 
2. TRPM8, INFLAMMATION AND PAIN 
Pain is defined by the International Association for the Study of Pain (IASP) as an 
“unpleasant sensory and emotional experience associated with actual or potential tissues 
damage, or described in terms of such damage”. 34 Pain results from activation of 
specialized peripheral nerve fibers, called nociceptors, by a noxious stimulus.
35
 The cell 
bodies of nociceptors are located in the dorsal root ganglia (DRG) for the body and the 
trigeminal ganglion (TG) for the face, and have both a peripheral and central axonal 
branch that innervates their target organ and the spinal cord, respectively. These 
receptors respond to various external stimuli: mechanical (i.e., pressure, tumor growth, 
incision) thermal (i.e., hot or cold), or chemical (i.e., ischemia or infection). Pain 
represents a key evolved survival mechanism to detect potentially damaging stimuli and 
thereby warn of the risk of injury. Unlike acute pain, pain arising after a lesion or 
disease of the peripheral or central nervous system (inflammatory and neuropathic pain) 
is often persistent, a chronic state. Hypersensitivity to mechanical, thermal and/or 
chemical stimulation is one of the hallmarks of inflammatory and neuropathic pain, 
which can manifest in the form of allodynia and/or hyperalgesia.
 36-38
 Hypersensitivity 
has been associated with increased excitability of nociceptor neurons as a result of 
changes in the expression of ion channels, receptors and mediator substances involved 
in the transduction processes.
 36, 39
 TRP channels are involved in these processes and 
play an important role in the first step of primary afferent sensitization.
40
 Therefore, 
their modulation has been considered, in the last decade, a prominent approach to 
develop new therapies for chronic pain syndromes.
 41, 42
 Identifying the mechanisms 
used by nociceptors to transduce noxious cold has lagged behind progress in 
understanding heat transduction mechanisms.
43, 44
  
TRPM8 channels are expressed by ≈5% of all somatosensory neurons, including mostly 
small-diameter, unmyelinated C-fibers, as well as a minor group of lightly myelinated 
Aδ fibers in dorsal root ganglia (DRG) and trigeminal ganglia (TG), and have been 
identified as candidates for cold sensing.
 45-48
 A subset of the TRPM8-positive cells may 
co-express TRPV1 and/or CGRP, but are not labeled by other known somatosensory or 
nociceptive markers (e.g., purinergic receptors, IB4 lectin, or neurotrophin receptors), 
placing them in their own anatomically and functionally unique subpopulation of 
primary afferent neurons.
49, 50
 In vivo, TRPM8 knockout mice are deficient in detecting 
innocuous cool temperatures and exhibit a partially defective phenotype in responding 
to both normal (acute) cold sensation and injury-evoked cold hypersensitivity. 
However, low temperature (>5 °C) induced cold pain was intact in these animals.
51-54
 
Activation of TRPM8 by the agonist menthol or icilin decrease nociceptive response in 
several animal pain models, including neuropathic pain caused by chronic constriction 
injury (CCI), inflammatory pain induced by injection of complete Freund’s adjuvant 
(CFA), and a peripheral demyelination model of inflammatory and neuropathic pain.
27, 
55
 Also, TRPM8 activation with icilin leads to potent anti-inflammatory effects with 
decreased mucosal damage in two different models of chemically induced colitis (DSS, 
TNBS) that are not observed in TRPM8-null mice.
55
 Paradoxically, TRPM8 antagonism 
may also provide relief from some forms of pain. For example, TRPM8 knockout mice 
failed to develop cold allodynia after chronic constriction injury or CFA injection.
56
 
Similarly,  a TRPM8 antagonist reduced cold allodynia in a chronic constriction injury 
model of chronic neuropathic pain, thus recalling the phenotype of genetic deletion.
57
 
Lastly, it has been shown that the administration of TRPM8 agonist menthol induced 
behavioral visceral pain-like responses in a mouse colitis model, which decreased by 
pre-treatment with a specific TRPM8 channel blocker.
58
  Zou et al., observed also an 
exacerbated cold hypersensitivity in an orofacial neuropathic pain model rat after 
treatment with menthol, a cold allodynia/hyperalgesia that was alleviated after 
administration of a TRPM8 inhibitor.
 59
  
Recently, different work showed that the ablation of TRPM8 afferents in the adult 
mouse leads to more profound deficits in cold behaviour compared to TRPM8 knockout 
animals.
60 
These results suggest the presence of TRPM8-independent transduction 
mechanisms in TRPM8 neurons, thereby providing cold sensitivity in the absence of 
TRPM8 channels. Other receptor molecules that have been linked to cold transduction 
include TRPA1,
61
 channels involved in signal propagation, such as Kv1 and two-pore 
(K2P) potassium channels,
62, 63
 and the sodium channels Nav1.8 and Nav1.9.
64, 65
 In 
addition to acute responses, cold pain associated with inflammation and nerve injury 
was significantly attenuated in ablated and knockout mice. Moreover, cooling-induced 
analgesia after nerve injury was abolished in both genotypes. These data confirm 
previous reports on the involvement of TRPM8 in cooling-induced pain relief,
27
 but 
show for the first time the absence of analgesia in TRPM8 knockout mice in a 
neuropathic pain model, and demonstrate that this pain-relief mechanism requires 
signaling via TRPM8 afferent nerve fibers. Importantly, TRPM8-deficient mice retain 
normal sensitivity to noxious heat and mechanical stimuli, demonstrating specificity of 
the observed phenotypes for cold sensation, as well as functional separation of these 
somatosensory/nociceptive modalities. This observation was confirmed in a recent 
study with spinal nerve-ligated (SNL) rats treated with a topical TRPM8 agonist, a 
1,2,4-triazole derivative (M8-Ag).
66
 This agonist inhibited neuronal responses to 
innocuous and noxious cooling in SNL rats, with no effect in the control group, and did 
not alter neuronal responses to mechanical, heat or brush stimulation.  
Preclinically, TRPM8 has been functionally linked to pain in oxaliplatin-induced
67
 and 
chronic nerve injury neuropathic pain models,
 28, 68
 where increased receptor expression 
and sensitivity to menthol or icilin were observed. In oxaliplatin-treated cancer patients, 
an increased sensitivity to menthol suggests TRPM8 overexpression or potentiation of 
its activity.
69
 These preclinical evidences for TRPM8 ion channels as a novel analgesic 
target have been translated to clinical benefit in patients with cancer-associated 
neuropathic pain, one of the most feared symptoms in cancer, particularly in terminally 
ill patients. Recently, Fallon et al.
70-72
 reported the analgesic benefit from the 
application of topical menthol to treat Chemotherapy-induced Peripheral Neuropathy 
(CIPN) and Post-mastectomy Pain Syndrome (PMPS). The first clinical results showed 
that the eighty-two per cent of evaluable patients had an improvement in their total pain 
scores after 4–6 weeks of treatment. Fifty per cent had a clinically relevant reduction in 
pain scores of at least 30 %, allowing continuation of life prolonging treatment.  
Finally, patients with idiopathic detrusor overactivity have increased TRPM8 
expression in bladder sensory neurons.
73
 These patients also show involuntary sustained 
bladder contractions, and reduced bladder threshold volumes in response to installation 
of ice-cold water into the bladder, an effect absent in healthy adults.
74
 In addition to a 
potential role in cold detection and pain, TRPM8 has been demonstrated preclinically to 
have a fundamental homeostatic role in the control of core body temperature, with 
TRPM8 antagonists causing significant hypothermia.
75
 However, Winchester et al.
76
 
have demonstrated that the use of selective TRPM8 antagonists induce analgesia in an 
experimental model of cold pain in humans, with efficacy equivalent to the 
therapeutically relevant semisynthetic opioid oxycodone and without a concomitant 
change in core body temperature. 
The involvement of TRPM8 channels in migraine is one aspect of the pain field that still 
remains unclear. Migraine is a very common neurobiological headache disorder 
associated with nausea, vomiting and photo- and phonophobia symptoms that is caused 
by increased excitability of the CNS. It ranks among the world’s most disabling medical 
illnesses.
 77
 Indirect evidences, such as expression and function of TRP channels in the 
cortex and trigeminal afferent fibers, suggest a mechanism for the initiation of migraine 
pain by activation, among others, of TRP channels on meningeal nociceptors after 
cortical spreading depression (CSD) or local inflammation.
78, 79
 
Identification of common genetic variants associated with migraine susceptibility has 
been a real breakthrough in the understanding of migraine molecular bases as well as in 
determining a potential TRPM8-migraine relationship.
80
 The identification of a TRPM8 
gene variant (2q37.1, rs10166942) is associated with increased susceptibility to 
common migraine. In 2015, a re-evaluation of key findings from candidate gene-
migraine association studies provided clear evidence for the involvement of TRPM8 in 
migraine, and showed no evidence for the participation of TRPV1 and TRPV3.
81, 82
 The 
exact role of the TRPM8 variant is unknown, as is the association of TRPM8 and 
migraine. However, these data allow hypothesizing that, regardless of being or not a 
migraine specific susceptibility gene, this TRPM8 variant may have a role in more 
general pain sensitivity mechanisms, such as the cutaneous allodynia present in the 
majority of migraine patients. 
 
3. TRPM8 IN CANCER 
Cancer is a life threatening disease, and even though a plethora of cancer drugs exist for 
various ailment types, current treatment regimens have important associated problems, 
and for many cancer types there is still no known cure. In this respect, the number of 
TRP channels that have been linked to carcinogenesis and tumor progression has 
considerably increased in recent years.
83-87
 Focusing on TRPM8 channels, they are 
overexpressed in a number of malignant tumors, especially solid tumors, being involved 
in different stages of cancer development, proliferation, migration and invasion.
88, 89
 
In 2001, L. Tsavaler and co-workers reported the identification of a new gene trp-p8, 
which was preferentially expressed in normal prostate epithelial tissue, and up-regulated 
in prostate tumor cells.
11
 The transcription polypeptide (1104-mer) of this gene showed 
a very high homology to a human-melastatin TRP channel identified a year later by G. 
Reid and M. L. Fonta,
90
 which described a new ionic channel activated by cool and 
sensitized by menthol, the TRPM8 channel.
11
 Tsavaler et al. observed that the 
overexpression of TRPM8 in prostate cells correlates with prostate cancer progression. 
Their studies also revealed the overexpression of trp-p8 gene in a number of neoplastic 
tissues other than prostatic, like breast, colon, lung, and skin.  
The expression of TRPM8 in prostate cells is closely related to androgen receptor (AR) 
activity, being clearly downregulated in cells in which this activity is cut out.
91-93
 In 
fact, Prevarskaya and co-workers demonstrated that TRPM8 expression is AR 
controlled in normal, hyperplasic and cancerous human prostate apical cells, while the 
loss of TRPM8 expression can be connected to either a high grade of tumor 
development, with undifferentiated cells (metastasis), or to a AR-independent tumor, 
where androgen receptor is not expressed.
93
 Moreover, TRPM8 expression has been 
observed in the androgen-dependent prostate cancer (PCa) cell line LNCaP, but not in 
the androgen-independent PCa cell lines PC-3 and DU-145.
11, 91
 However, expression of 
TRPM8 in the androgen-independent PC-3 cells was reported later by Zhang et al.
92
 
Several experiments modulating TRPM8 expression in the androgen-sensitive cell line 
LNCaP by using menthol and cooling as activators of the channel, and capsazepine as 
channel antagonist, provided evidence of the role of TRPM8 as mediator of Ca
2+
 influx 
and release from intracellular stores, in both plasma membranes and in the endoplasmic 
reticulum.
92, 94
 These results together with those of siRNA experiments confirmed that 
normal function of TRPM8 is required for tumor cell survival. Later research showed 
that TRPM8 is expressed both in the plasma membrane, TRPM8PM, and in the 
endoplasmic reticulum, TRPM8ER. TRPM8PM channel is found only in highly 
differentiated prostate epithelial cells, while TRPM8ER is not dependent on the 
differentiation status. Further experiments revealed that functional AR seems to be 
mandatory for TRPM8PM activity, while TRPM8ER activity is independent. They also 
observed that the transition to PCa upregulated TRPM8 expression is both in plasma 
membrane and reticulum. It was suggested that TRPM8PM is important for the Ca
2+
 
signaling involved in proliferation, while TRPM8ER can be considered essential in 
controlling the growth of advanced PCa metastatic cells.
95
 This hypothesis is consistent 
with the model proposed by Hendriksen et al. in which progression from high-grade 
PCa to metastasis is mediated by selective downregulation of the AR pathway genes.
96
 
It seems clear then, the benefit of androgen–ablation therapy in early stages of prostate 
cancer, but still there are doubts about the role of TRPM8 in the androgen-independent 
cell lines, and in advanced grade tumors. Recent work of Zhu et al. proved that artificial 
overexpression of TRPM8 in the AR-independent cancer PC-3 cell line, in vivo, has a 
negative effect on the proliferation and angiogenesis progression. These results open 
new opportunities for the potentiation of TRPM8 channels as treatment for patients in 
advanced stages of cancer and metastasis.
97 
Despite all these results that evidence the correlation of TRPM8 with prostate 
carcinogenesis and tumor progression, there was still controversy around the idea of 
whether the aberrant expression of TRPM8 in PCa is the origin or the result of tumor 
development. In this sense, Pardo and co-workers designed several experiments that 
shed light on this question. They studied the consequences of TRPM8 silencing, both 
pharmacologically blocking and siRNA experiments, which showed that proliferation 
was reduced only in all tumor prostate cells tested, but not in normal prostate cells. It 
seems that the proliferation of normal cells is not affected by TRPM8 downregulation. 
These interesting results support the idea that TRPM8 plays a tumor specific role in 
tumor proliferation instead of being a mere consequence of tumor development.
98
 
Concerning diagnoses, the biomarker currently used in clinic for prostate cancer, is the 
prostate-specific antigen (PSA). However, its usefulness is questionable because PSA 
can be found in serum samples of both PCa patients, and patients with benign prostatic 
hyperplasia. Moreover, the PSA levels are quite similar in patients with 
localized/quiescent PCa and in patients with metastasis.
99
 The higher presence of 
TRPM8 compared to PSA, in malignant tissue samples in comparison to non-malignant 
ones, suggests TRPM8 as a useful biomarker for PCa diagnosis.
100
 Bai et al. had found 
that the TRPM8 levels in urine and blood of patients with metastasis were significantly 
higher than in patients with localized cancer, that have underwent radical prostatectomy, 
as well as than those of healthy men. These findings suggest that TRPM8 levels in body 
fluids can be a useful prognosis biomarker, which will permit to distinguish between 
clinically localized and metastatic prostate cancer. Their experiments also confirmed the 
role of TRPM8 in androgen regulated proliferation of prostate cancer cells, although 
they are in some way contradictory with the results found for TRPM8 expression in 
organ tissues.
101
  
The number of tumors in which upregulation of TRPM8 has been detected has 
increased in the last decade. Tsavaler et al. already reported it in lung, skin, breast and 
colon cancer tissues.
11
 Since then, it has also been identified in neuroblastoma, 
osteosarcoma, urothelial carcinoma, in which it was associated with poor survival, and 
pancreatic adenocarcinoma, where it was shown to correlate with tumor stages.
89
 
Chodon et al. found correlation between TRPM8 expression and the breast cancer grade 
in the MCF-7 cell line, and interestingly they also found correlation with estrogen 
receptor alpha (ERα) levels.102 This proves that the regulation of TRPM8 in breast 
cancer cells is hormonal dependent, which is in agreement with the androgen-dependent 
regulation of TRPM8 in prostate cancer cells.
11, 93
 Additionally, experiments performed 
by Okamoto et al. suggest that TRPM8 channels are functional on the plasma 
membranes in human oral squamous carcinoma cell lines HSC3 and HSC4.
103
 
Experiments to assess the biological response in the presence of TRPM8 agonists and 
antagonists led to demonstrate that the stimulation of TRPM8 increases MMP-9 
activity, while its blockade has the opposite effect, which can be translated in the 
increased metastatic potential induced by TRPM8.
103
 The group of Yee has 
demonstrated that TRPM8 is consistently over-expressed in human pancreatic 
adenocarcinoma cell lines and tissues, and that patients with this type of tumor 
aberrantly exhibit immunoreactivity against the TRPM8 channel.
104, 105
 They also 
evidenced that RNAi-mediated silencing of the TRPM8 gene stimulates replicative 
senescence, thus suggesting that abnormally expressed TRPM8 channels could 
contribute to pancreatic tumorigenesis.
105
  
 
4. TRPM8 IN OTHER PATHOLOGICAL CONDITIONS 
Apart from inflammation and cancer, TRPM8 channels are related to other pathological 
conditions, although they have been less studied and their role is less established.
85 
For instance, there is evidence that link TRPM8 channels to respiratory disorders. Thus, 
the mitigating effects of menthol in the irritant responses to certain tobacco smoke 
constituents had been reported.
106, 107
 These effects were reverted by the treatment with 
a TRPM8 antagonist. Besides, the stimulation of TRPM8 channels can be harmful in 
patients with asthma and also with chronic obstructive pulmonary disease (COPD). In 
fact, cold-induced airway hyperresponsiveness can either induce asthma or exacerbate 
COPD and asthma, increasing morbidity. Cold-air inhalation causes airway constriction 
and can induce asthma associated with, for instance, winter sports.
107, 108
 These 
observations suggest the implication of TRPM8 channels both in physiological and 
pathological respiratory processes. 
TRPM8 channels are also implicated, together with other TRPs (mainly TRPV1), in 
bladder sensation, showing a high interest as therapeutic targets for lower urinary tract 
dysfunction (LUTd).
109
 Several studies suggest the relevant role of TRPM8 in disorders 
like bladder pain syndrome and bladder hyperactivity.
109, 110
 The observation of 
upregulation of TRPM8 in bladder tissues of patients with painful bladder syndrome or 
idiopathic detrusor overactivity (IDO), in comparison to healthy controls, points in this 
direction, but the correlation of TRPM8 expression and these abnormalities still remain 
unclear.
111
  
Concerning obesity, there are two types of adipose tissue in mammals, the white (WAT) 
and the brown (BAT). The BAT is in charge of energy expenditure through the 
activation of the UCP1 protein, inducing thermogenesis, which can prevent the 
development of obesity. The work reported by Ma et al. showed that menthol promotes 
the overexpression of UCP1 in cultured brown adipocytes from wild-type mice, but not 
in TRPM8-deficient mice.
112
 Recent work reported by Rossato et al.
113
 showed that 
menthol or icilin activation of TRPM8 in WAT enhanced the UCP1 expression, having 
as a consequence an increase in glucose uptake and heat-production. The authors 
interpret these results as an induction of the brown phenotype in white adipocytes, 
which points to TRPM8 as a potential target for the treatment of obesity.
113
 Moreover, 
certain connection between TRPM8 gene polymorphisms and obesity-related metabolic 
syndrome has also been established.
114
 
The presence of TRPM8 has also been detected in blood vessels, being the most 
abundant among the TRP channels in these tissues.
115, 116
 TRPM8 expression has been 
observed in several rat arteries, and its activation by menthol or icilin promoted 
vasodilation. This vasodilation, induced by systemic administration of menthol, may be 
responsible for the fall in arterial blood pressure observed in an in vivo study in rabbits 
and cats. It has also been reported that the vasoconstriction or vasodilation depends on 
the previous vasomotor tone, and that it is mainly mediated by TRPM8 activation on 
smooth muscle cells.
17
 Although results of other research in this area are in agreement 
with these observations,
117-119
 further research is still required to confirm the real 
mediation of TRPM8 in vasodilation-related processes. 
Experimental studies from the group of Belmonte and co-workers showed that reduction 
of temperature and subtle osmolality increases can stimulate DRG and TG neurons 
expressing cold-sensitive TRPM8 channels, which act as regulators of surface wetness 
of exposed body mucosae, like the eye.
120, 121
 Therefore, another function of the 
TRPM8-expressing neurons is to act as regulators of ocular wetness through the 
modulation of the blink rate, thus predicting new opportunities for the understanding 
and treatment of dry eye, a common ophthalmological disorder that increased with age.  
 
5. TRPM8 AGONIST CHEMOTYPES 
5.1. Menthol and derivatives.  
Chemical modification of endogenous ligands or natural products, capable of interfering 
with a given receptor, is a widely used strategy in medicinal chemistry programs.
122, 123
 
Therefore, not surprisingly, the exploration of menthol-derived compounds emerged 
shortly after the discovery that menthol activates TRPM8 channels,
45
 with ester 
derivatives like Frescolat ML,
124
 carboxamide analogues such as  1 (WS-12, Figure 
2),
125
 described as the first high-affinity TRPM8 ligand,
125
 and fluorinated analogues 
claimed as the basis for diagnostic agents.
126, 127
 Sherkheli et al. also quantified the 
activation of TRPM8 channel by several menthol carboxamide derivatives, some of 
which were initially prepared by Wei, E.T. et al. and others, finding up to 10-fold lower 
EC50 values than for the parent menthol.
128
  It seems that the cyclohexyl ring, 
characteristic of menthol, is behind the enhanced selectivity of the most representative 
derivatives in this series, 1, 2 (WS-5),
128
 and 3 (CPS-125)
128
 (Figure 2), when compared 
to lower homologues and linear analogues.  
 Figure 2. Menthol and derived TRPM8 agonists 
Dendreon Coorporation described related derivatives in several patents. Their menthol-
derived small-molecules, illustrated by compounds 4-6, are able to activate TRPM8 
with nanomolar potency.
129, 130
 In this family of compounds, the substituted cyclohexyl 
moiety and the free amino groups seem desirable structural requirements for good 
agonist activity, while the carboxamide substituent accepts bezimidazolone (D3263, 4), 
phenyl (5) and substituted ethyl (6) derivatives. In addition of increasing Ca
2+
 entry in 
CHO cells expressing TRPM8, selected compounds from this series prove to stimulate 
cancer cell apoptosis, and substantially reduce xenograft tumors in animal models of 
human prostate cancer, without showing apparent toxicity. Compound 4 from this 
series, showing good oral bioavailability, entered Phase I clinical trials in 2009 for the 
assessment of safety, determination of the maximum tolerated dose, and 
characterization of the pharmacokinetic profile after a single dose and repeated daily 
dosing (NCT00839631). In men with advanced prostate cancer, preliminary results 
indicated that this compound is able to stabilize the disease. Apart from elevations in 
Troponin-T, no signs of cardiac toxicity were observed (Maximun tolerated dose: 100 
mg/day).
131
 Last updated data at ClinicalTrials.gov was April 30
th
, 2012. Some 
preclinical data also demonstrated the potential of 4 to treat benign prostatic hyperplasia 
by itself or in combination with the synthetic 5α-reductase inhibitor finasteride (additive 
effect). 
Some diastereomeric menthol ethers, like 7, have been described in a recent Japanese 
patent  to display nanomolar activation of the TRPM8 receptors.
132
 Menthol-related 
cyclohexane-hydantoin spirocyclic derivatives, as well as pyrazolyl-5-one and 
pyrimidinetrione analogues, have also been claimed as TRPM8 effectors (structures not 
disclosed).
133 
Despite numerous studies on its applications in cosmetics, which are not being 
commented here, there are several clinical trials evaluating the usefulness of menthol 
alone or in combination with other active principles as a therapeutic agent. A few of 
these studies are recorded here, including their ClinicalTrials.gov identifier number. 
Thus, menthol alone or Biofreeze®, a topical lotion containing menthol and alcamphor, 
is being examined for treating pain symptoms in slaughterhouse workers with 
symptoms of Carpal Tunnel Syndrome (NCT01716767),  as a topical counter-irritant on 
cutaneous pain and hyperalgesia provoked by topical application of TRPA1-agonists 
(NCT02653703), to alleviate shoulder pain (NCT01827306), musculoskeletal disorders 
associated to neck pain (NCT01542827), and persistent neuropathic pain from 
chemotherapy among breast and colorectal cancer patients (NCT01855607). 
An invention by researchers at the Edinburgh University also claims that activation of 
TRPM8 channels induces analgesia in chronic neuropatic pain states.
134
 Therefore, 
activation agents including menthol and menthyl derivatives, among others, could be 
useful for the treatment of diseases and conditions which involve neuropathic pain, such 
as that induced by trauma, demyelination, cancer or inflammatory states, phantom-limb, 
back and bone pain, and chemotherapy neuropathy. 
As a potential alternative for the prevention and treatment of hypertension, the Third 
Military Medical University is evaluating the effects of menthol on blood pressure in 
hypertensive patients (a double-blind phase II clinical study, NCT01408446). 
Studies performed with two different human melanoma cell lines expressing TRPM8, 
reported the dose-dependent in vitro cytotoxic effects of menthol.
29, 135
 Chanchao and 
coworkers had in fact stated an effectiveness comparable with that of 5-FU, with the 
advantage that menthol has no toxicity, while the side-effects of 5-FU are multiple and 
non-negligible.
135
 Menthol also showed a significant decrease on the viability of a 
bladder cell line T24, inducing cell death through TRPM8 activation.
136 
Inventors from the Miguel Hernández University have patented that the TRPM8 
receptor is linked to the control of lacrimation, and that its activation with agonists, like 
menthol, increased tearing, thus leading to a promising remedial for the dry eye 
condition.
137
 As agonists they studied menthol, frescolat, geraniol, eucaliptol, icilin and 
other cooling agents. The invention also relates the use of TRPM8 antagonists as useful 
treatment for epiphora (excessive tear production). 
The activity and interest of various natural and synthetic menthol derivatives, along 
with other cooling compounds that behave as activators of thermoTRPM8, have been 
compiled in a 2012 comprehensive review.
138 
5.2. Pyrimidine derivatives.  
Icilin  is a synthetic compound that behaves as an agonist of TRPM8 (about 200-fold 
more potent than menthol),
26, 139
 but also suppressed TRPM8 current activation by other 
agonists,
22
 and modulates TRPV3,
140
 and TRPA1.
22
 Therefore, icilin has been and 
continues being used as a pharmacological tool for studying TRP channels.
141-143
 Icilin 
has anti-inflammatory activity,
55
 has been claimed for the treatment of different 
neurological disorders, as menthol and linalool,
144
 and reduces the activity and 
expression levels of E2F1,
145
 a transcription factor controlling the cell cycle in prostate 
cancer cells.  The group of De Petrocellis explored the preparation of new analogues by 
modification of  the pyrimidin-2-one central scaffold of icilin, in an attempt to improve 
the therapeutic potential.
146
 Work at the three rings of the icilin molecule demonstrated 
very narrow limits for modification. SAR studies point to the importance of the 
presence and position of the o-OH and m-NO2 substituents on the distal phenyl groups. 
The phenyl ring at 1-position of the pyrimidine central scaffold tolerates some 
variations, like the addition of a methyl group in relative para position to the OH or the 
presence of m-halogens (I < Br > Cl) in non-OH analogues, but always provided less 
potent compounds.  Either a lower homologue of the central ring or conformationally 
restricted tricyclic derivatives were totally inactive.
146 
 Figure 3. Pyrimidine-derived TRPM8 agonists 
 
Structurally unrelated pyrimidine derivatives, exemplified by compound 8, produce 
cooling effects on skin and mucous membranes through the interaction with the TRPM8 
receptor (submicromolar potencies).
147
 
5.3. Five-membered heterocycle derivatives 
In a recent paper by R. Patel and coworkers, compound 9 (M8-Ag), with a 1,2,4-triazole 
central scaffold, was described to display more potent anti-hyperalgesic effects than 
menthol in a rat model of  neuropathic  pain.
66
  This compound activates TRPM8 
channels with a 45 nM EC50 value and also TRPA1 thermoreceptors, although with 
lower potency (4 M). It attenuates neuronal responses after innocuous and noxious 
cooling, and reverses hypersensitivity to acetone-induced cooling in spinal nerve-ligated 
(SNL) rats. Results from this study led the authors to suggest that TRPM8 agonists 
might be beneficial in neuropathy without affecting normal cold sensation.  
The group of Ostacolo described the preparation of a family of isoxazole derivatives 
and their preliminary characterization as TRPM8 agonists.
148
 From the 12 isoxazole 
collection, some compounds were more potent than menthol (up to 200-fold), but most 
of them display lower efficacy. A few compounds, like 10, elicit stronger allodynic 
responses than menthol in rats with chronic constriction injury of the sciatic nerve. 
 Figure 4. 1,2,4-Triazolyl- and isoxazolyl-derived TRPM8 agonists 
 
5.4. Other TRPM8 agonists 
Different plant-derived natural products have been identified as TRPM8 agonists, 
including eugenol,
12
 eucalyptol,
124
 geraniol,
124
 and neferine,
149
 all of them displaying 
moderate to low potency ranging from M to mM EC50 values (Figure 5). The 
activation/sensitization to cold of mammalian TRPM8 seems to be responsible for the 
enhancement of innocuous cold and noxious cold sensations induced by camphor, 
which also potentiate heat sensations through activation of TRPV1 and TRPV3 
channels.
150
  
5-Methyl-2-(1-pyrrolidinyl)-2-cyclopenten-1-one (11), isolated from roasted malt,
151
 
and some hybrid derivatives,
152
 were identified as intense cooling compounds. Although 
authors mentioned TRPM8 channels as cold-sensitive receptors, no data is provided 
regarding the direct action of these compounds on the mentioned thermoreceptor.  
In patch-clamp experiments, eucalyptol, from eucalyptus oil, evokes inward currents in 
TRPM8-expressing cell, and also behaves as a TRPA1 antagonist, while its regioisomer 
1,4-cineole  activates both receptor types.
153
Studying different small-molecules BASF 
SE identified new chemotypes able to activate TRPM8 channels.
147, 154
 Thus, a series of 
tetrahydrofuro[3',4':5,6]pyrido[2,1-a]isoquinoline-dione derivatives, exemplified by 
compound 12, and different secondary caffeic-derived amides, like derivative 13, show 
submicromolar potencies (Figure 5). 
Wei described in a recent patent a series of new di-isopropyl-phosphinoyl alkene 
(DIPA) compounds for the topical treatment of sensory discomfort (itch, dermatitis, 
psoriasis, and ocular discomfort, among others).
155
 In this series, the 
i
Pr group is 
preferred over sec- or iso-butyl homologues, and optimal length for the linear aliphatic 
alkene is 6 to 9 carbon atoms. These compounds elicit submicromolar EC50 values and 
>5-fold increased potency compared to menthol (i.e., 14, Figure 5). A related phosphine 
oxide, containing sec-butyl substituents instead of iPr, was previously studied, showing 
a dose-dependent and reversible activation of TRPM8 with an EC50 value of 4.1 μM.
156
 
While studying a series of N-Aryl and N-benzyl triptamine derivatives to explore the 
structural requirements determining TRPM8 modulation, Bertamino and co-workers 
described a new compound able to activate the channels under investigation (15, Figure 
5).
157
  Thus, triptamine derivative 15 displays significantly higher potency (EC50 = 40 
µM) than menthol, and a similar efficacy under patch-clamp experiments.  
 Figure 5. Natural products and other TRPM8 agonists.  
 
6. TRPM8 ANTAGONIST CHEMOTYPES  
During the last decade, several pharmaceutical companies and a few academic groups 
have made enormous efforts in the search for new antagonists of the TRPM8 channel. 
The different families of compounds described to date are recorded in this section, with 
an intended rational classification, based first on the central structural scaffold and then, 
if necessary, subcategorizing them by other secondary motifs. 
6.1. N-Heteroaryl-N-benzyl sulfonamides.  
6.1.1. Benzothiophene derivatives. Several patents from Janssen claimed the interest of 
a big family of benzothiophene-bearing N-benzyl sulfonamides (examples 16-20), and 
related N,N’-disubstituted analogues (21), as potent TRPM8 antagonists (Figure 6). A 
first patent describes 850 benzo[b]thiophene derivatives and some aza-analogues 
through the combination of different substituents at position 3 of the bicyclic skeleton, 
at the N-benzyl susbstituent and at the sulfonyl moiety.
158
 Preliminary HTS evaluation 
was performed in an in vitro canine TRPM8 functional assay, measuring the changes 
produced by compounds in the intracellular Ca
2+
 concentration induced by the agonist 
(menthol or icilin). From the results of this assay, it can be said that chlorine, bromine, 
or small alkyl groups are preferred at position 3, while at the benzyl moiety a m- or p-
fluorine or trifluoromethyl group, or a combination of them, favored TRPM8 antagonist 
properties. Either alkyl or aryl groups at the sulfonyl moiety are well tolerated. The 
antagonist properties for the most promising compounds were confirmed through patch 
clamp experiments. Thus, representative compound 16 exhibits high potency either in 
the hTRPM8 HTS assay (IC50: 4 nM) or in patch clamp experiments (IC50: 1.1 nM and 
2.3 nM, after menthol and cold activation, respectively). The potent TRPM8 antagonist 
properties were confirmed in different animal models: by reversing carrageenan-
induced heat hypersensitivity (64% at 30 mg/Kg, p.o.) and CFA-induced thermal and 
mechanical hyperalgesia (91% at 10 mg/Kg, p.o.). This compound was also able to 
reduce icilin-stimulated “wet-dog” shakes (WDS) in rats with an ED50 of  2.5 mg/Kg, 
cold-evoked cardiovascular pressor responses (75% of inhibition), and acetone-induced 
hypersensitivity, an in vivo model of neuropathic pain (69% pain relief, 30 mg/Kg, 
p.o.). A 
18
F labeled analogue of 16, its related derivative 17 and the 
11
C labeled 
compound 18 were also protected as useful tools for the labeling and imaging of 
TRPM8 channels.
159
 One year later of the initial patent in this series, Janssen published 
an extension that covered potent aminoethylsulfonyl derivatives, like 19, and some less 
active naphthalene analogues.
160
 Closely related sulfamides, exemplified by compound 
20 in Figure 6, also afforded TRPM8 antagonists with nanomolar potencies in the HTS 
assay, although their efficacy in animal models was not revealed .
161
  
At the beginning of 2012, Janssen published the US patent 0053347 describing a new 
series of benzothiophene derivatives, resembling to some extent previous series in this 
section, but bearing a phosphonate moiety instead of the initial sulfonamide.
162
 The 3-
bromothiophene 21, with a 9 nM IC50 value in the HTS functional assay and good 
antagonist in vivo activities, is one of the most active compounds in this series. Thus, 
this compound reverses up to 80% the icilin-induced behaviors in rats (30 mg/Kg, p.o.), 
and several compounds within this family are also active in the CFA-induced model of 
hyperalgesia (ED50 up to 5.2 mg/Kg). As it could be expected, the configuration of the 
asymmetric center of 21 is important for the antagonistic activity, with its R-enantiomer 
and the racemic form showing one-order of magnitude lower potencies. An initial SAR 
study, including a part of the compounds covered by the patent, has been published, and 
highlights the preference for small alkyl groups at position 3 of the benzothiophene 
ring, and either ethyl or isopropyl esters alongside the phosphonate.
163 
 Figure 6. TRPM8 antagonists: Compilation of representative N-benzothiophene 
sulfonamides and related compounds 
 
6.1.2. Benzimidazole derivatives. A second family of TRPM8 antagonists with a central 
N-sulfonamide motif includes compounds substituted with a benzimidazole moiety 
(examples 22, 23, Figure 7). A couple of patents protect the TRPM8 antagonist activity 
of the mixtures of 1,3- and 1,2-N-disubstituted derivatives, initially obtained after 
benzylation of the corresponding 1-monosubstituted analogues.
164, 165
 In these series, 
low alkyl groups at the N1 atom are well tolerated (ethyl preferred), and one or two 
fluorine atoms or a CF3, or a combination of both, at the phenyl ring of the benzyl 
moiety increase potencies with respect to unsubstituted analogues, as it was also found 
for the incorporation of F or CF3 at position 5 of the benzimidazole nucleus.  
In general, the best compounds within these collections were less potent than 2-alkene 
substituted benzimidazole related derivatives, which displayed nanomolar potency in 
the canine hTRPM8 Ca
2+
-flux assay.
166
 A representative compound in this new series, 
24, is able to reverse cold hypersensitivity in a model of neuropathic pain (oral 10 
mg/Kg, 91%), and icilin-induced WDS (oral 30 mg/Kg, 98%), even if it does not show 
optimal PK properties regarding metabolism.
167 
Analogues of 24 bearing spiroheterocyclic systems in position 2 of the central skeleton 
provided highly potent TRPM8 antagonists, with IC50 values in the subnanomolar 
range.
168
 In this series, the dihydro isoxazole ring is preferred over the oxazole and 
imidazole at the spiro moiety. Compound 25 inhibits cold-stimulated currents in HEK 
cells expressing hTRPM8, reverses icilin-induced behaviors in rats (98%, 10 mg/Kg, 
p.o.), and reduces neuropathic pain (acetone-mediated hypersensitivity, 83%). This 
compound exhibits a good pharmacokinetic profile, with excellent oral bioavailability 
and relatively high metabolic stability.
57
  
Related azabenzimidazole derivatives, substituted with different pentaheterocycles at 
position 2, here represented by compound 26, are also patented.
169
 Chlorine, alkyloxy 
and substituted amines are the groups of choice at 7-position, while pyrazole ring 
provided the most potent compounds among all the 2-pentaheterocycles incorporated in 
this series. 
 
Figure 7. TRPM8 antagonists: Representative N-benzimidazole sulfonamides and 
related compounds. 
 
6.1.3. Pyridine derivatives. Two patents on N-benzyl-N-pyridylsulfonamide structures, 
similar to those described in the previous sections, have been disclosed by RaQualia 
Pharma.
170, 171
 In a first series of 199 compounds, exemplified by the N-pyridine 
derivative 27 (RQ00203078, Figure 8),
170
 the observed activities indicated the need for 
a 3-Cl atom on the pyridine ring, combined with CF3, CH3 or Cl groups at position 5. In 
addition, the incorporation of different substituents at the phenyl ring of the benzyl 
moiety either maintain or improve the activity, as it does the change of the carboxylic 
acid by a hydroxymethyl group or differently substituted carboxamides. In the second 
set of compounds, the phenyl ring of the benzyl substituent has successfully been 
replaced by diverse heterobicycles, like benzofuran, indole, indazole, and benzotriazole 
derivatives. In these patents, the inventors claimed for good in vitro antagonist 
properties in HEK293 and human malignant melanoma cell lines, and also indicated 
potent activities in different in vivo models, although there is no disclosed data about 
that. They also claim for beneficial effects of their compounds on neuropathic pain of 
cold- and static-allodynia, icilin-caused WDS, oxaliplatin-induced pain, and overactive 
bladder in rats suffering from cystitis.  A recent paper by this group describes that 
compound 27 attenuates the shaking behavior with an ED50 of 0.65 mg/kg (p.o.), 
indicating that this sulfonamide derivative is a potent and orally active TRPM8 
antagonist. This compound, which is commercially available as a pharmacological tool, 
is also selective over other TRP channels (A1, V1, V4) and has been selected as an 
advanced compound for further investigation.
172
  
Related analogues having a condensed pyridine moiety (isoquinoline) have been 
patented by Mitsubishi Tanabe Pharma Corporation (see compound 28 in Fig. 8).
173
 
Among these very potent compounds, the presence of the cyclopropyl group is an 
important structural requirement, while the tetrazole group (a carboxylic acid isostere) 
can be substituted by other nitrogen-containing heterocycles, like tetrazolone, 1,2,4-
triazole and 1,2,4-oxadiazole-5-one, and even by CO2H, CO2Me and CN groups without 
significant loss of antagonist activity. Similarly, different groups are allowed at ortho-
position of the tetrazole moiety, with Me, OMe, Cl and NMe2 within the preferred ones. 
 
Figure 8. TRPM8 antagonists: Representative pyridine-derived N-Heteroaryl 
sulfonamides and related compounds. 
 
In 2010, Glenmark patented a new family of compounds, which keeps an N-heteroaryl 
(benzothiazole or benzoxazole) and an N-benzyl moiety on a nitrogen atom, but differs 
from previous series in the third N-substituent.
174
 Instead of the sulfonyl appendage, 
these tertiary amines bear an alkylamino moiety, as illustrated by compound 29. In this 
series, unsubstituted benzo[d]thiazol-2-yl and benzo[d]oxazol-2-yl led to potent 
derivatives, and some aza analogues are acceptable. The presence of F atoms (2- or 2,4) 
or a 2-methyl group in the benzyloxy moiety is coupled to high activity, as the m-OMe 
group on the N-benzyl substituent. 
 6.2 Urea derivatives. 
The (3-chloro-pyridin-2-yl)-piperazine derived urea (BCTC, 38) has been one of the 
first TRPM8 antagonists used for studying the pharmacology of this channel (IC50: 0.8 
M, Figure 9).124 This compound, which is commercially available, was initially 
prepared as a TRPV1 modulator (IC50: 35 nM), therefore is a non-selective TRPM8 
antagonist. Probably, in the search for more potent and selective TRPM8 antagonists, 
this compound inspired the design and synthesis of other urea derivatives as those 
described in the two following subsections.   
6.2.1. Tetrahydroisoquinolines and aza-analogues. In 2009, Amgen Inc. published two 
patents describing tetrahydroisoquinolines and aza-analogues as TRPM8 antagonists, 
and claimed their potential value for the treatment of diverse pathologic conditions.
175, 
176
 In their efforts to validate TRPM8 channel as a novel target for pain, they discovered 
a tetrahydrothienopyridine derivative after a high-throughput screening campaign. The 
initial hit was then modified to lead to tetrahydroisoquinoline-urea analogues with 
higher potency and increased metabolic stability.
177
 In this series, modification at the N-
phenyl ring is restricted to the incorporation of F atoms or its replacement by 
unsubstituted pyridine rings. Although with suboptimal pharmacokinetic properties, 
compound 31 (Figure 9) reduces icilin-induced WDS in a dose dependent manner (80%, 
30 mg/Kg, po). Further optimization of potency and pharmacokinetic properties 
afforded analogues 32 and 33, with hTRPM8 IC50 values of 10 and 12 nM, respectively, 
and balanced properties that made them ideal for in vivo evaluation.
178
 In the icilin 
induced rat−wetdog shakes (WDS) model, compound 32 achieves maximal inhibition at 
10 mg/kg (p.o.), while 33 results in 68% inhibition of WDS at 1 mg/kg, and the icilin 
effect was completely blocked at 3 mg/kg. Compared to the initial hit 31, the higher in 
vivo activity of 33 was attributed to the increased drug plasma levels, which results from 
the improved pharmacokinetic properties of the latter molecule. This compound was 
selected for further progression in preclinical models of pain.  
 Figure 9. TRPM8 antagonists: Representative urea derivatives. 
 
6.2.2. Spiro[chromene-2,4’-piperidine] derivatives. Following an analogue-based 
rational design, synthesis and screening, Glenmark Pharmaceuticals discovered a set of 
spiro[chromene-2,4’-piperidine]phenylureas that behave as TRPM8 antagonists (see 
derivative 34 in figure 9).
179, 180
 Selected compound 34 shows nanomolar in vitro 
TRPM8 potency, moderate to high metabolic stability in different species, and 
quantifiable levels in plasma up to 8 h post-dose following oral administration. The R-
stereoisomer is more potent and more selective over other TRP channels than its optical 
S-antipode. In in vivo models of neuropathic pain, 34 is able to inhibit the acetone-
induced allodynia in rats (74%, 10 mg/Kg, p.o.), significantly reduced the icilin-induced 
WDS in mice (72% efficacy, 30 mg/Kg, p.o.), and produced a dose-dependent 
inhibition of paw licking after oxaliplatin injury (100% effect, 30 mg/Kg, p.o.).
180 
6.2.3. Other urea derivatives. Very potent TRPM8 antagonists, containing a central urea 
motif have been patented by Bayer.
181
 Compound 35 is one of the most potent TRPM8 
antagonist described to date, displaying subnanomolar potency in the menthol-induced 
Ca
2+
 influx in TRPM8-expressing HEK293 cell assay (Figure 9). 
 
6.3. Phenylglycine derivatives.  
Another collection of TRPM8 antagonists is that of N-arylphenylglycine amides, 
described by Janssen Pharmaceutica (i.e., 36, Figure 10).
182, 183
  This family comprises 
two libraries of 375 and 55 compounds, in which 2-arylpyrrolidine and isoquinoline 
substituents gave better activities than other mono- and bis-heterocyclic systems. 
Substituted phenyl and benzothiophene are preferred aryl moieties at the α position of 
the amino acid. As expected, the influence of the configuration was crucial for the 
activity of these Phg derivatives. Thus, compound 36 (S,S) shows one-order of 
magnitude higher potency than its (R,R) and (R,S) isomers, while the (S,R) 
diastereoisomer undergoes more than 100-fold drop in the antagonist activity, indicating 
a larger influence on the activity of the pyrrolidine stereogenic center than that of the 
Phg residue. Compound 36 demonstrated good in vivo efficacy reducing WSD in rats 
produced after administration of icilin.
183 
Related phenylglycine amides, combining either a differently substituted N-(R)-inden-1-
yl ring or a 1-phenylethyl group with an N-acyl moiety, bearing aryl- or heteroaryl 
groups, have been recorded in two recent patents by Kissei Pharmaceutical.
184, 185
 
Preferred compounds from these series are able to reduce the icilin-evoked wet-dog 
shakes in rats (i.e., derivative 37, 100% inhibition at 3 mg/Kg). These compounds also 
elongate significantly the micturition interval in guinea pigs (up to 221% at 0.5 
mg/Kg/mL).  
 Figure 10. TRPM8 antagonists: Illustrative phenylglycine derivatives. 
 
6.4. Tryptamine derivatives.   
The structural requirements behind TRPM8 modulation were also explored by means of 
a series of N-substituted tryptamines. Apart from the already mentioned agonist 15, 
most derivatives within this series behave as TRPM8 antagonists, with the (N,N-
dibenzyl-2-(1H-indol-3-yl)ethanamine (38) as the most potent inhibitor of calcium 
influx in HEK293 cells.
157
 Perfusion of tryptamine derivative 38 (3 M) produced a 
complete inhibition of menthol-induced TRPM8 currents measured at +80 mV, with 
kinetics slower than that observed for 30 (BCTC), but increased potency (38, IC50 = 367 
nM).  
5-Substituted tryptamine derivatives were also identified as antagonists of TRPM8 after 
screening of the Renovis corporate collection and further evaluation of commercial 
analogues.
186
 Compound 39, identified as the most potent tryptamine derivative within 
this family, lacks of selectivity since it is a known ligand of 5-HT receptors.
187
  
Voacangine, a conformationally restricted tryptamine-derived natural product, 
competitively displaces menthol, but not icilin, from TRPM8 receptors (IC50 = 9 
M).188 This compound is a stimulus-selective antagonist, because it did not abrogate 
cold-induced channel opening but inhibited chemical agonist-provoked TRPM8 
activation. In addition, voacangine competitively inhibits capsaicin binding on TRPV1, 
and blocks capsaicin- and heat-induced activation of this thermoreceptor, and shows 
some TRPA1 agonist activity.   
 
Figure 11. TRPM8 antagonists: Selected tryptamine derivatives. 
 
6.5. Tertiary amide derivatives.  
A collection of 177 2-benzyloxy-benzoic acid amide derivatives were protected under 
patent by Bayer Healthcare AG.
189
 The prototype N-(2-thienylmethyl) derivative  
(AMTB, 40, IC50 = 8 nM, Figure 12)
189
 in this series was used as a pharmacological tool 
to learn that, in rats, this TRPM8 blocker attenuated bladder micturition reflex, without 
affecting the contraction amplitude, and reduced nociceptive reflex responses to noxious 
bladder distension.
190
  
More recently, Pfizer and collaborators described new salicyl amide derivatives with 
improved properties.
191
 Thus, following a lead-hopping strategy on the closely related 
40 (AMTB) analogue 41, they prepared three libraries with decreasing degree of 
similarity. Compound 42 from one of these libraries displays improved potency (IC50 = 
21 nM), and better lipophilic efficiency compared to 41. 
The HTS screening of the Pfizer in house collection allowed the identification of 
another tertiary amide derivative with weak inhibitory properties of TRPM8 receptors, 
which upon optimization resulted in the quinolin-3-carboxamide derivative PF-
05105679 (43).
192
 Modifications at the acidic group resulted in reduced potency, while 
at the other benzylic residue only the incorporation of a m-chlorine atom is well 
tolerated. Its potency against TRPM8 was confirmed by patch-clamp electrophysiology 
studies, and selectivity was assessed through evaluation in a set of different receptors, 
enzymes and ion channels, including related thermoreceptors (TRPV1 and TRPA1) and 
hERG. In preclinical studies, compound 43 exhibited good oral absorption, moderate 
blood clearance and low toxicity. In humans, a single 900 mg dose was effective in a 
cold pressor test (Phase I, NCT01393652), without significant changes in core body 
temperature, but intolerable hot sensation side effects precluded further progression into 
the clinic. 
 
Figure 12. TRPM8 antagonists: Archetypal tertiary amide derivatives. 
 
6.6. Other recent TRPM8 antagonists with variable central scaffolds. 
6.6.1. Cyclohexane-hydantoine spirocyclic derivatives. Patent WO2015136947 from 
Raqualia Pharma Inc. communicates the preparation of a big collection of  1,3-
diazaspiro[4.5]decane-2,4-dione derivatives and their 1-oxa-3-azaspiro analogues (~600 
examples), among which an array of 42 compounds potently inhibited the Ca
2+
 influx 
through HEK293 cell expressing hTRPM8 (IC50 < 10 nM, i.e. 44, Figure 13).
193
 
Although a central phenyl ring seems to be preferred, some heterocyclic moieties, like 
pyridine, imidazole and pyrrole are allowed at this position. The phenyl ring could bear 
a diverse set of nitrogen heterocycles, including indole, 1-benzimidazole, isoquinoline, 
and different aza analogues, with the 7-aza-1-benzimidazole as the most repetitive motif 
in highly active compounds. Although without displaying specific data, the inventors 
claimed for in vitro inhibition of the Ca
2+
 influx through a melanoma cell line (G-31), 
and potent in vivo activities in different neuropathic pain models and on micturition 
frequency. 
 
 Figure 13. Structure of other structurally diverse TRPM8 antagonists.  
 
6.6.2. Thiazole derivatives. A patent from Dompé Farmaceutici SpA revealed a series 
of compounds with a thiazole or isoxazole central scaffold with interesting activities as 
TRPM8 antagonists in vitro and in vivo.
194
 The phenyl thiazole derivative (DFL23448, 
45), was then fully characterized in collaboration with different academic groups.
195
 It 
shows an IC50 value of 10 nM in cold-activated hTRPM8 HEK-293 cells, being 
selective against other TRP channels (TRPV1, TRPA1, TRPV4) and different G-
protein-coupled receptors. In in vivo experiments in rats, 45 is able to reduce icilin-
induced wet-dog shakes (10mg/kg, i.v), prolongs the storage phase of micturition and 
inhibits bladder overactivity.  
6.6.3. Menthol derivatives.  A series of menthylamine derivatives, embodied by 
compound 46, elicited potent TRPM8 antagonist properties, being between 4- and 150-
fold selective against TRPV1 and TRPA1 channels.
196
 When tested on a human 
androgen-responsive prostate carcinoma cell line, which over-expresses TRPM8, 
compound 46 induces apoptosis, measured by the release of caspase 3/7. However, in 
the androgen-unresponsive DU-145 tumor cell line, this compound is inactive, 
indicating a TRPM8-dependent antitumor activity. This compound was also progressed 
to Ph I clinical trials.  
6.6.4. Chroman derivatives.  A big series of azachroman derivatives was protected 
under patent WO 2014025651 by Amgen Inc.
197
 Exemplified here by compound 47, a 
number of these derivatives displayed nanomolar activity in the luminescence assay of 
intracellular calcium (CHO expressing hTRPM8). The most potent antagonists were 
able to inhibit >90% the wet-dog shakes in rats at 1mg/Kg dose. These compounds 
combine in the molecule key structural elements of other families of TRPM8 
antagonists, akin to the chroman heterocyclic ring present in 34 (Figure 9) and a 
heterocyclic moiety, like the benzimidazole profusely used within the sulfonamide 
derivatives. 
Clinical trials (Phase I, NCT01953341, NCT02132429) have been started with 
AMG333 (structure not disclosed) to define safety and tolerability, and to characterize 
the pharmacokinetic (PK) profile, as well as its effect on the cold pressor test (CPT)-
induced increase in blood pressure after single oral doses in healthy individuals and 
subjects with migraine.  
6.6.5. β,γ-Diaminoesters. Selective antagonists for TRPV1, TRPM8 (48) and TRPA1 
channels, as well as dual TRPV1/TRPM8 and TRPM8/TRPA1 ligands, were obtained 
after modification of a linear β,γ-diaminoester scaffold.198 In this family, no significant 
differences in activity were found among diastereoisomers of the same compound, 
suggesting that they could accommodate within a big pocket within these TRP channels. 
Lessons extracted from the preferred substituents for the selective blockade of these 
three TRP channels could serve to design new potent and selective TRP blockers. 
6.6.6. Cinnamamide derivatives. Some open-chain cinnamamide derivatives, as 49, 
primarily prepared as intermediates in the synthesis of icilin derivatives, displayed 
pronounced TRPM8 antagonist activity and acceptable selectivity over TRPV1.
146
 
Halogens or aliphatic groups at meta-position of the aniline-derived ring provide the 
most potent antagonists, with the m-iodo derivative 49 showing a 73 nM IC50 value. 
6.6.7. 3-Ylidenephthalides. A new template that resulted in novel TRP channel 
modulators was the 3-ylidenephthalides. Thus, Ortar and coworkers described that these 
type of compounds act as TRPM8 antagonists (50, Figure 13), but also as strong 
modulators of TRPA1 (activators and desensitizers).
199 
6.6.8. Others. Some approved antifungal drugs as clotrimazole and econazole  are also 
good blockers of TRPM8 channels.
200, 201
 The phenylethyl imidazole (SKF-96365, 
51),
202
 an inhibitor of receptor-mediated Ca
2+
 entry with blocking actions on several 
TRPC channels, also targets and blocks TRPM8 receptors (IC50 = 0.8 M).
51 
 
6.7. Natural products and derivatives as TRPM8 antagonists 
The well-known TRPV1 activators capsaicin and resiniferatoxin inhibit the effect on 
Ca
2+
 induced by icilin, but not by menthol, on TRPM8-HEK-293 cells (micromolar and 
submicromolar potencies, respectively).
203
 Anandamide and N-arachidonoyl-dopamine  
(NADA, Figure 14),
204
 endogenous ligands of TRPV1 and CB1 receptors, behaved as 
TRPM8 antagonists by inhibiting the Ca
2+
 entry stimulated both by icilin and 
menthol.
203
 Similarly, other cannabinoid structures of natural origin, like THC, THCA, 
cannabigerol, and cannabidiol are able to block the TRPM8 channel activation, but in 
general are nonselective against other TRP channels.
205
 Cannabigerol, a known non-
psychotropic cannabinoid is able to reduce cell viability in the colorectal cancer cell line 
CACO-2 by promoting apoptosis, which was confirmed by the increased activity of 
caspase 3/7.
206
  This effect on cell viability was mimicked by two other 
phytocannabinoids, which also block TRPM8, and what is more important, TRPM8 
silencing resulted in a lower cytotoxic effect. In vivo experiments performed both in 
xenograft and AOM (azoxymethane) models of colon cancer showed that cannabigerol 
reduces and even prevents the tumor growth. The antitumor activity of cannabidiol on 
prostate cancer cell lines has also been reported.
207
 These results suggest cannabigerol, 
cannabidiol and related non-habit analogues could be promising agents in cancer 
treatment. 
Sphingoid-like compounds, like leucettamols A and B obtained from a marine sponge, 
inhibit icilin-induced activation of TRPM8 channels.
208
 These compounds also target 
the cold-sensitive TRPA1 receptors, but are inactive on TRPV1 and the cannabinoid 
receptors. 
Some geraniol, nerol, and citronellol derivatives behave as TRPM8 antagonists on 
TRPM8-HEK293 cells, the nerol chain being particularly effective in this respect. 
Compound 52, with an IC50 value of 0.29 μM in the TRPM8 assay, was selective 
against TRPV1 but acts as a strong modulator of TRPA1 channels (EC50 and/or 
IC50 values <1 μM). 
209
 Similarly, thymol derivatives, here exemplified by compound 
53, are true TRPM8 antagonists, but as for most phytochemicals with TRPM8 activity, 
also display strong TRPA1 modulation.
210
 
 
Figure 14. Structure of phytochemicals and derivatives acting as TRPM8 antagonists. 
 
7. INSIGHTS INTO THE TRPM8 STRUCTURE 
In the lack of a crystal structure, little is known about the structure-function of TRPM8, 
and the scarce structural information available is coming from mutagenesis experiments 
and molecular modeling studies.  
Similarly to voltage-gated potassium (Kv) and like other TRPs, TRPM8 channels have 
six α-helices forming the transmembrane architecture (S1-S6). Among them, S1-S4 
segments constitute the sensing domain (SD) and S5 and S6 constitute the pore (PD). 
The intracellular N-domain, with an important role in targeting TRPM8 to the plasma 
membrane, and also the inner C-terminal domain, containing the TRP and coiled-coil 
subdomains required for gating and channel assembly, complete the protein.
211, 212
 The 
S4 transmembrane and the S4-S5 linker are responsible for voltage sensing, S6 is 
involved in the selectivity for cations, and the S2-S3 linker seems to be implicated in 
the interaction with icilin, the same region that has been recognized in the activation of 
other TRPs by chemical agonists.
213
 It has been demonstrated that the initial N-terminal 
region of TRPM8 is important for correct biogenesis and function, since truncation of 
the 1-40 segment augment TRPM8 responses to menthol and cold, and elimination of 
the 40–60 region afforded non-functional channels that are retained in the ER.214 The 
group of Edwardson, by means of atomic force microscopy (AFM) imaging, has 
showed that the TRPM8 channel assembles as a tetramer, with a centrally located 
pore.
215
 These authors  suggestthat this assembly pattern is common to other TRP 
members, as they had previously shown for TRPC1,
216
 and recently has been elegantly 
confirmed by the group of Julius, which has solved the structure of  TRPV1 through 
electron cryo-electron microscopy.
217 
High-throughput random mutagenesis studies on the TRPM8 thermosensor proved that 
residues in S2 and S4 transmembrane segments are important for menthol-induced 
channel opening, and voltage and temperature activation.
218
 Namely, Y745 in S2 and 
R842 in S4 were designated as chief residues for channel opening and menthol 
dependent currents through TRPM8. Y745 is also critical for the inhibition of cold- and 
voltage-activated TRPM8 currents mediated by 51, but not by other antagonists like 30, 
clotrimazole,  and econazole, suggesting multiple binding sites on these channels.
201
 
Very recent NMR experiments on the interaction between menthol and the hTRPM8-
SD corroborate that R842 and Y745 are essential residues for the interaction, and 
indicated that more likely ligand binding produces a conformational change in the 
sensor domain that results in channel gating.
219
 
Chimeric TRPM8 channels containing segments of the S6-TRP box linker of TRPV1 
permitted the identification of residue Tyr981 as a key molecular determinant of 
channel function, while mutations in the 986–990 region influenced channel gating by 
voltage and menthol. Based on these results and on the electron cryo-electron 
microscopy model of TRPV1, the group of Ferrer-Montiel generated a molecular model 
of TRPM8 and hypothesized that residue Tyr981 and region 986–990 may be involved 
in inter-subunit interactions between the TRP domain and the S4–S5 linker (Figure 15). 
If the TRP domain participates in channel opening, the modulation of protein-protein 
interactions within this domain may constitute a new strategy for channel modulation 
and/or drug intervention. 
220 
 
 Figure 15. Homology model of the tetrameric assembly of TRPM8 channel viewed 
from the lateral (left) and the intracellular (right) side. Each monomer is differently 
colored. 
 
Based on the above model,  Bertamino et al. proposed two pharmacophore prototypes 
for their series of tryptamine-based TRPM8 modulators, identifying a unique binding 
site for both agonist and antagonist derivatives (15 and 38, Figures 5 and 11, 
respectively), but differing in the interaction network.
157
 TRPM8 complexes with these 
compounds are stabilized by similar hydrophobic interactions with Leu843, Ile701, 
Leu697, a π−π stacking with Tyr754, and electrostatic pairs with the Glu1004 side 
chain. The indole NH proton of agonist 23 makes hydrogen bonds with  Tyr754 
phenoxy group and with the backbone of Arg1008, increasing the Arg1008-Glu1004 
distance when compared to that measured for the TRPM8-38 complex, and promoting 
an evident shift of the TRP domain helix.  Further mutagenesis studies are needed to 
corroborate the structural hypothesis depicted from these pharmacophore models. 
Pedretti and coworkers generated a full-length computer model for the hTRPM8 
channel, following a fragmental strategy, exploiting the homology with other channel to 
construct the monomer, namely the voltage-dependent Shaker family of K+ channel for 
the transmembrane region and the structure of HCN2 channel for the C-terminal 
domain.
221
 Protein–protein docking was then used to assemble monomers into the 
corresponding homotetramer. Docking with menthol, icilin and other ligands resulted in 
good agreement with mutagenesis studies, confirming that S4 and S4–S5 loop are 
crucial for channel activation. 
The TRPM8 transmembrane and pore helix region has been studied by Bidaux et al. 
using a combination of molecular modeling and experimental techniques.
222
  As for 
other members of the TRP family, they identified that the DDDD ring was essential for 
the pore of TRPM8, with the length of side-chains and the negative charges of these 
residues being crucial in TRPM8. However, unlike for other TRP channels, the negative 
charge of TRPM8 D920 residue is not enough to select divalent cations, but participates 
to the facilitation of cation conductance. This study also demonstrated that residue Y908 
in the P-helix is implicated in menthol and cold-mediated TRPM8 activity, but not in 
icilin recognition. Whether menthol binds directly to the P-helix or to the binding site 
on the S2 pocket, inducing a conformational change on the pore domain remains to be 
elucidated. 
 
8. ENDOGENOUS REGULATION OF TRPM8 
Traditionally, a large effort has been devoted to modulate ion channels, including 
TRPM8, considering that they are isolated proteins inserted in a cell membrane. 
However, it is becoming evident that ion channels are members of protein networks that 
notably influence their activity. Furthermore, channel activity is highly regulated in a 
context-dependent manner, with the interplay of diverse cellular components, including 
lipids, proteins and metabolites. In this regard, the activity of TRPM8 is prone to 
endogenous regulation for fine-tuning its activity to a proper cellular response. 
Accordingly, TRPM8 dysfunction appears also affected by regulatory pathways, as their 
malfunction may impact TRPM8 function.
223
 Undoubtedly, the most studied 
endogenous TRPM8 regulatory mechanism is its dependence on PI(4,5)P2.
31
 It is well 
documented that PI(4,5)P2 modulates both activation and desensitization of the 
channel.
31
 Hydrolysis of PI(4,5)P2 by phospholipases type C (PLCγ, PLCβ and PLC) 
abrogates channel function, while resynthesis of the original PIP2 restores its channel 
activation.
223
 Regulation of TRPM8 by phosphoinositides can also be mediated by the 
phosphoinositide interacting regulator of TRP (Pirt), a protein that increases the 
sensitivity of TRPM8 to menthol and cool temperatures.
224
 This protein acts 
synergistically with PI(4,5)P2 to augment TRPM8 channel activity.
225 
PI(4,5)P2 levels are largely modulated by the activation of PLC through G-protein 
coupled receptors (GPCR) and Receptor Tyrosine Kinase (RTK). Activated PLC 
enzymes hydrolyze PI(4,5)P2 to phosphoinositol trisphospate (PIP3) and diacylglycerol 
(DAG). These two components act synergistically to activate PKC, which in turn may 
phosphorylate TRPM8. Furthermore, PIP3-induced release of Ca
2+
 from the 
endoplasmic reticulum activates calmodulin kinase that can also phosphorylate 
TRPM8.
226
 A consequence of TRPM8 phosphorylation appears to be reduction of 
channel activity that further augments the inhibition produced by the hydrolysis of 
PI(4,5)P2. Complementarily, an increase in PKA activity also appears to inhibit TRPM8 
channel activity. Recently, a novel mechanism of TRPM8 inhibition by GPCRs that 
implies the direct inhibition of the channel by Gαq has been described.
227
 It is notable 
that most RTK and GPCRs sensitize TRPV1 channels, and concomitantly desensitize 
TRPM8 channels, which may underlie the heat hyperalgesia and abnormal cold 
sensations caused by inflammation.
227
   
The activity of TRPM8 is additionally modulated through two additional membrane-
related mechanisms. First, it has been documented its regulation by phospholipase A2 
(PLA2), an enzyme that generates lysophospholipids and arachidonic acid.
223
 
Intriguingly, these lipids modulate TRPM8 activity in some cellular systems but not in 
planar lipid bilayers. A plausible explanation is that PLA2 generates two antagonistic 
compounds as lysophospholipids tend to enhance TRPM8 activity and arachidonic acid 
inhibits the channel function.
228
 Because PLA2 normally enhance the menthol activity, it 
appears a prevalence of the lysophospholipid stimulating effect over the polyunsaturated 
fatty acids inhibitory action. Second, TRPM8 activity is also modulated by its location 
in membrane microdomains. For instance, it was reported that TRPM8 activity is 
downregulated by its partition in lipid rafts.
229
 However, a recent study reported just an 
opposite result as TRPM8 activity was reduced after disrupting the lipid rafts in 
trigeminal neurons.
230
 These results indicate a role of membrane microdomains 
modulating channel function although further studies are needed to clarify whether the 
discrepancies reported are due to different experimental conditions or determined by the 
cellular context.  Finally, the oxidative metabolite of linoleic acid 9(S)-HODE acts a 
non-selective TRPM8 antagonist, which also modulates TRPV1 and TRPA1 
channels.
231 
Apart from the lipid-mediated endogenous regulation, there is evidence that TRPM8 
function can be additionally modulated by short isoforms that emerge from post-
transcriptional regulation of the main protein transcript.
232
 These shorter channel 
isoforms inhibit TRPM8 activity by mimicking an increase in temperature as compared 
with the inhibitory activity exerted by chemical antagonists.
232
 Interestingly, a novel 
TRPM8 isoform has been identified in keratinocytes that is expressed in the 
endoplasmic reticulum of these cells, and endogenously contributes to the cold 
sensitivity of epidermal homeostasis by controlling the balance between keratinocyte 
proliferation and differentiation in a cold-dependent manner.
233
 Recently, it has been 
described that the vesicle-associated membrane protein 7 (VAMP7) is implicated in the 
functional plasma membrane incorporation of TRPM8, and therefore in regulating 
thermosensitivity.
234
  
Another important endogenous regulatory mechanism of TRPM8 arises from its 
sensitivity to sex hormones. As already mentioned, this channel was first identified as a 
biomarker of hormone-dependent prostate cancer cells, as its levels were high in these 
tumor cells.
11
 Asuthkar et al. report the interesting observation that the TRPM8 channel 
is a receptor for testosterone, suggesting a direct role of the hormone regulating the 
receptor activity.
235, 236
 Related to this observation, Gkika et al. discovered that the 
prostate cancer marker, prostate-specific antigen (PSA), is also a modulator of TRPM8 
activity.
237
 Indeed, they reported that PSA acts as a natural agonist of TRPM8 in the 
prostate and the channel activation by PSA results in a reduction of cancer cell motility. 
Overall, these findings suggest that modulation of TRPM8 may be an important strategy 
for anti-cancer drug intervention.  
In summary, endogenous regulation of TRPM8 channels provides new opportunities to 
modulate the receptor activity by acting in signaling pathways that convey into the 
channel.  
 
9. SUMMARY AND FUTURE PERSPECTIVES  
 
Over the past few years, there has been significant development in the field of TRPM8 
channels, regarding expression, polymodal activation, implication in diverse 
pathological conditions, and discovery of diverse modulators, both agonists and 
antagonists.
25, 33
 Cumulative evidence indicates the essential role of TRPM8 in virtually 
all aspects of cold thermal transduction, including innocuous and noxious cold, 
hypersensitivity to cold caused by inflammation, nerve injury or chemotherapeutic 
neuropathy, and regulation of core body temperature.
40
 Therefore, modulation of 
TRPM8 channel function to tune the excitability of cold-sensing neurons could have a 
broad clinical benefit in the management of chronic and/or neuropathic pain.
44
 Thus, the 
identification of new compounds targeting different binding sites of its signalplex may 
be anticipated as a realistic strategy for effectively and safely treating acute and chronic 
pain states, which is still a major unmet challenge in biomedical research. Regarding 
cancer, it is documented that in prostate tissues, TRPM8 channels play a different role 
depending of the cell type and also on the tumor grade, and progression, showing even 
different and opposite effects.
89
 TRPM8 expression in prostate cancer cells is androgen-
regulated, but its over-expression appears to be hormone-independent. TRPM8 
expression is substantially decreased in androgen-independent and metastatic prostate 
cancer. A number of other life-threatening tumors, like melanoma, neuroblastoma, and 
pancreatic adenocarcinoma, also over-express TRPM8 channels, although their 
particular role is mostly unknown.
88
 Therefore, there is still further research needed to 
completely elucidate the mechanisms by which TRPM8 exerts its biological activity and 
to understand its implications in tumorigenesis and cancer progression. Provided that 
activation or blockade of the TRPM8 channels may have opposite effects, depending on 
the type and stage of the tumor, their clinical significance remains to be proved. The 
proven involvement of TRPM8 channels in pain, cancer, and cancer-induced pain, and 
its validation as a molecular target, open the door to new global strategies for effective 
management of these pathologies. Concerning diagnosis, TRPM8 levels could be 
exploited as a clinical biomarker for the diagnosis of different cancer types. In fact, the 
TRPM8 detection in patient fluids samples (urine and blood) proved to be useful to 
discriminate between clinically localized prostate cancer and metastatic tumors.
86, 101
 
Furthermore, molecular imaging agents based on TRPM8 selective modulators could 
also have a major effect on the detection of cancer, as already proposed.
126
   
Increasing experimental evidences have also revealed that stimulation of TRPM8 
channels is involved in a number of pathological conditions, including thermogenesis of 
brown adipose tissue,
113
 asthma and COPD,
238
 urinary tract dysfunction,
239
 and eye 
wetness.
121
 Thus, TRPM8 provides promising new approaches to treat obesity, 
respiratory processes, bladder dysfunction, and certain ophthalmologic problems. 
Although a number of diverse TRPM8 modulators have been described, and resulted in 
an improved understanding of the structure-activity relationships within different 
families, their selectivity over other TRP channels, and in general over panels of diverse 
biological targets, is mostly unknown or not yet disclosed. Furthermore, taking into 
account that a unique chemotype could result in promiscuous ligands for different TRP 
channels,
198
 the existing pharmacological knowledge about TRPM8 modulators should 
be taken with caution. Another factor of paramount importance for the advancement in 
TRPM8 drug discovery will be to elucidate the receptor binding sites for the different 
families of modulators. At present, this is partly precluded by the scarce structural 
knowledge available, although progress in homology modeling may contribute in the 
near future.
157
 It is expected that further advances in structural biology could help in 
characterizing accurately TRPM8 ion channel−ligand interactions, thus increasing our 
understanding of ligand binding. In addition, it will contribute to apply rational design 
methodologies to hit discovery and to hit-to-lead optimization toward safer and more 
selective modulators. Nonetheless, until this information becomes available, existing 
screening methodologies provide a useful approach to discover novel TRPM8 
modulators and to develop analogues with improved therapeutic properties.  
As reviewed in this perspective, there are already few TRPM8 modulators that have 
reached clinical studies, and most of them are yet in phase I trials. Although the 
expectations are high, prediction of a clinical success based only on animal data appears 
premature at present. We have to wait for the results of proof-of-concept clinical studies 
to learn on the relevance of therapies based on TRPM8 modulators. 
Finally, the information accrued thus far also suggests that the operational function of 
TRPM8 depends on the cellular context and that different strategies, from membrane 
localization and dynamics to translation of short isoforms, are involved in defining the 
pathophysiological function of the receptor. This information should be taken into 
account in the design of the next generation of TRPM8 therapeutic drug candidates. 
Structure-function studies have unveiled that the TRP domain,
31
 a protein region 
adjacent to the channel gate, contributes to the allosteric coupling of stimuli sensing to 
gate opening, and it is the binding site of PI (4,5)P2.
220, 240
 Notably, peptides patterned 
after this domain in TRPV1 channels inhibit receptor function,
228
 indicating that this 
domain may also be a novel site for drug intervention in TRPM8 channels. Up to date, 
the destabilization of protein-protein interactions (PPI) within ion channels has barely 
been studied,
241
 but most probably the application of strategies followed for other PPIs 
could also be relevant for TRPM8 drug discovery. 
Another important point to be explored in the near future would be to analyze the 
clinical benefit of combined therapies or multifunctional drugs acting simultaneously on 
several TRPs, since sometimes more than one TRP channel is involved in the same 
pathological disorder (i.e., TRPM8 and TRPA1 in cold-induced pain and asthma). 
107, 
108, 242
  
Although ion channels remain underexploited in drug development, continued 
investigation into the discovery of new, selective TRPM8 agonists and antagonists will 
undoubtedly contribute to future progress in the field. The ability to combine advances 
in functional screening, biophysical characterization, and structure-based design 
techniques, along with the generation of new chemical space to target ion channels will 
constitute a substantial challenge for the drug discovery community in the following 
decade. We should be expectant for the clinical success of currently tested TRPM8 
modulators for the treatment of human diseases, from pain to cancer. 
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